SCORED Trial: Sotagliflozin Showed Robust MACE Benefit

Trial results for the 'twincretin' in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.
Medscape Medical News

source https://www.medscape.com/viewarticle/971487?src=rss